160337-95-1
Chemical Structure
Insulin glargine
- CAS No.: 160337-95-1
- Formula:C267H404N72O78S6
- Molecular Weight:6062.89
SMILES: O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CSSC[C@@H](C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H]([C@H](O)C)C(N6[C@@H](CCC6)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC7=O)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC8=O)C(N[C@@H](CSSC[C@@H](C(NCC(N[C@@H](CO)C(N[C@@H](CC9=CNC=N9)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC%10=CC=C(C=C%10)O)C(N[C@@H](CC(C)C)C(N[C@H]7C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(C)C)NC([C@H](CC%11=CNC=N%11)NC([C@H](CCC(N)=O)NC([C@H](CC(N)=O)NC([C@H](C(C)C)NC([C@H](CC%12=CC=CC=C%12)N)=O)=O)=O)=O)=O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H]8[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)CN
Biological Activity: Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Insulin glargine | 95.0% | Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Liu S, et al. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract. 2011 Feb;91(2):177-82. [Content Brief]
- [2]. Stammberger I, et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol. 2002 May-Jun;21(3):171-9. [Content Brief]
- [3]. Li Y, et al. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice. Med Sci Monit. 2018 May 19;24:3293-3300. [Content Brief]
- [4]. Hwang HG, et al. Recombinant Glargine Insulin Production Process Using Escherichia coli. J Microbiol Biotechnol. 2016;26(10):1781-1789. [Content Brief]
Keywords
